BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21402712)

  • 1. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Shi Z; Tiwari AK; Shukla S; Robey RW; Singh S; Kim IW; Bates SE; Peng X; Abraham I; Ambudkar SV; Talele TT; Fu LW; Chen ZS
    Cancer Res; 2011 Apr; 71(8):3029-41. PubMed ID: 21402712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
    Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
    Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
    Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
    Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of sildenafil in enhancing drug sensitivity in cancer.
    Shi Z; Tiwari AK; Patel AS; Fu LW; Chen ZS
    Cancer Res; 2011 Jun; 71(11):3735-8. PubMed ID: 21610107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
    Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
    J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
    Ding PR; Tiwari AK; Ohnuma S; Lee JW; An X; Dai CL; Lu QS; Singh S; Yang DH; Talele TT; Ambudkar SV; Chen ZS
    PLoS One; 2011 Apr; 6(4):e19329. PubMed ID: 21552528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
    Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
    Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
    Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
    PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.